Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors

Active, not recruitingOBSERVATIONAL
Enrollment

670

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

April 16, 2033

Study Completion Date

April 16, 2033

Conditions
Carcinoid Heart Disease
Interventions
OTHER

Study of the occurrence of Carcinoid Heart Disease

"Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, …) biological parameters (urinary 5HIAA, NT-ProBNP …) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease."

Trial Locations (19)

31059

CHU Rangueil, Toulouse

33604

CHU Bordeaux - Hopital Haut-Lévèque, Bordeaux

35000

CHU Rennes, Rennes

37044

CHRU Tours, Tours

49933

CHU Angers, Angers

59000

GHICL Lille, Lille

59020

Centre Oscar Lambret, Lille

59037

CHRU Lille, Lille

67098

Hôpital Haute Pierre, Strasbourg

69437

Hôpital Edouard HERRIOT, Institut du Cancer - Hospices Civils de Lyon, Lyon

75014

APHP - Hopital Cochin, Paris

75571

APHP - Saint Antoine, Paris

80054

CHU Amiens, Amiens

86021

CHU Poitiers, Poitiers

92118

APHP Beaujon, Clichy

94805

Institut Gustave Roussy, Villejuif

Unknown

CHU Dijon, Dijon

Institut Paoli-Calmettes, Marseille

CHU Reims, Reims

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03498040 - Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter